Correspondence 0001193125-23-145379 from Neuphoria Therapeutics Inc. (NEUP) (CIK 0001191070) (NEUP)
Neuphoria Therapeutics Inc. (NEUP) (CIK 0001191070)
Date: May 15, 2023 · CIK: 0001191070 · Accession: 0001193125-23-145379
AI Filing Summary & Sentiment
File numbers found in text: 333-271696
Letter
VIA EDGAR Division of Corporation Finance Office of Life Sciences Attention: Tyler Howes Re: Bionomics Limited Registration Statement on Form F-3 File No. 333-271696
Dear Mr. Howes:
Pursuant to Rule 461 of Regulation C of the General Rules and Regulations under the Securities Act of 1933, as amended, the undersigned, on behalf of Bionomics Limited (the “Company”), respectfully requests that the effective date of the Registration Statement on Form F-3 referred to above be accelerated so that it will become effective at 4:00 P.M. Eastern Time on May 17, 2023, or as soon as practicable thereafter.
Please contact Michael E. Sullivan of Latham & Watkins LLP, counsel to the Company, at (858) 523-3959, to provide notice of effectiveness, or if you have any questions or require additional information regarding this matter. Thank you for your assistance and cooperation in this matter.
Very truly yours,
BIONOMICS LIMITED
Show Raw Text
CORRESP 1 filename1.htm CORRESP Bionomics Limited 200 Greenhill Road Eastwood SA 5063 Australia May 15, 2023 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street N.E. Washington, D.C. 20549 Attention: Tyler Howes Re: Bionomics Limited Registration Statement on Form F-3 File No. 333-271696 Dear Mr. Howes: Pursuant to Rule 461 of Regulation C of the General Rules and Regulations under the Securities Act of 1933, as amended, the undersigned, on behalf of Bionomics Limited (the “Company”), respectfully requests that the effective date of the Registration Statement on Form F-3 referred to above be accelerated so that it will become effective at 4:00 P.M. Eastern Time on May 17, 2023, or as soon as practicable thereafter. Please contact Michael E. Sullivan of Latham & Watkins LLP, counsel to the Company, at (858) 523-3959, to provide notice of effectiveness, or if you have any questions or require additional information regarding this matter. Thank you for your assistance and cooperation in this matter. Very truly yours, BIONOMICS LIMITED By: /s/ Spyridon “Spyros” Papapetropoulos Spyridon “Spyros” Papapetropoulos President, Chief Executive Officer and Director cc: Michael E. Sullivan, Latham & Watkins LLP Nathaniel Ajiashvili, Latham & Watkins LLP